ENLIVEN THERAPEUTICS INC (ELVN) Stock Income Statement
NASDAQ:ELVN - Nasdaq - US29337E1029 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 110.26M | 104.55M | 83.53M | 34.27M | 51.44M | |||
| Research and Development | 85.70M | 80.78M | 64.57M | 18.94M | 38.44M | |||
| Selling, General, and Administrative Expenses | 24.56M | 23.78M | 18.95M | 15.33M | 13.00M | |||
| Operating Income | -110.26M | -104.55M | -83.53M | -34.27M | -51.44M | |||
| Interest Income/Expense | 15.71M | 15.76M | 11.97M | 940.00K | 230.00K | |||
| Other Income/Expense | -48.00K | -2.00K | -22.00K | -100.00K | -180.00K | |||
| Non Recurring Items | N/A | N/A | N/A | 35.00M | N/A | |||
| Income Before Taxes | -94.60M | -88.79M | -71.58M | 1.58M | -51.38M | |||
| Income Tax | N/A | 232.00K | N/A | 90.00K | N/A | |||
| Net Income | -94.83M | -89.02M | -71.58M | 1.49M | -51.38M | |||
| EBITDA | -109.95M | -104.24M | -83.23M | -33.66M | -51.34M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.93 | -1.89 | -2.01 | 0.23 | -9.49 | |||
| Non GAAP EPS | -1.92 | -1.89 | -2.19 | N/A | -3.99 | |||
| Statistics | ||||||||
All data in USD